Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Non-Hodgkin Lymphoma
Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkin's L
November 26th, 2008
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that Clinical Cancer Research has published in the November 1, 2008 issue the results of a study authored by Samual Jacobs et al. investigating the use of short-course CHOP-R followed by Zevalin ([90Y]-ibritumomab tiuxetan) and extended rituximab as first-line treatment in follicular non-Hodgkin's lymphoma patients. Addition of the Zevalin therapeutic regimen increased the complete responses from 40% for patients evaluated after 3 cycles of CHOP-R alone to 82% after the Zevalin regimen. "This study adds to recently published First-line Indolent Trial (FIT) data indicating that the addition of Zevalin in...
Source: Immunotherapy Weekly (2008-11-26)
|
